Skip to contentS
Supernus Pharmaceuticals, Inc.
S
SUPNSupernus Pharmaceuticals, Inc. Q1 2024 · 10-Q
Revenue$143.64M$143.64M−6.6% vs Q1 2023 Net Income$124.00K$124.00K−99.3% vs Q1 2023 EPS Diluted$0.00$0.00−100.0% vs Q1 2023 Operating Income-$3,153,000N/M Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Supernus Pharmaceuticals, Inc. · CIK 1356576 · Engraved from SEC EDGAR
Free Cash Flowderived$38,153,000−21.9% Margins · derivedOperating margin-2.2%−5.6 pt vs Q1 2023
Net margin0.1%−10.9 pt vs Q1 2023
ended Mar 31, 2024 · filed May 8, 2024 · 38 d after period end